ALGS

Business Context and Reporting Period

Company: Aligos Therapeutics, Inc. (ALGS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Aligos is a clinical-stage biotechnology company developing novel therapeutics for liver diseases (chronic Hepatitis B virus, MASH) and viral infections (coronaviruses). The company has no products approved for commercial sale and has incurred significant losses since inception. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: Net income for the six months ended June 30, 2025, includes a non-cash gain of $63.176 million from the change in fair value of 2023 common warrants. Without this gain, the company would have reported a net loss.

Material Changes vs. Prior Period

• Revenue: Total revenue decreased by approximately 38% year-over-year for the six-month period, driven by the near completion of the original agreement with Amoytop and the start of an extension agreement. Revenue from collaborations was $0 for the current period compared to $292,000 in the prior year.
• Operating Expenses: Total operating expenses decreased by 23% ($11.4 million) compared to the prior year. This reduction was primarily due to a decrease in third-party clinical study costs following the completion of the MASH Phase 2a clinical trial, partially offset by increased spending in the chronic HBV infection program.
• Net Income/Loss: The company reported a net income of $27.2 million for the six months ended June 30, 2025, compared to a net loss of $29.8 million in the prior year. This swing is almost entirely attributable to the $63.2 million gain on the remeasurement of the 2023 common warrants liability.
• Liquidity: Cash, cash equivalents, and short-term investments increased significantly to $122.9 million as of June 30, 2025, from $56.9 million at the end of 2024. This increase was driven by a $105.0 million gross proceeds PIPE offering in February 2025.

Guidance, Outlook, and Risks

• Capital Resources: Management expects existing cash, cash equivalents, and investments to fund operations for at least 12 months following the report date. The company anticipates needing substantial additional financing to achieve its goals, which may not be available on acceptable terms.
• Clinical Pipeline Updates:
  • ALG-000184 (HBV): Phase 1 data showed sustained HBV DNA suppression. The Phase 2 B-SUPREME study is expected to commence dosing in the coming weeks, with interim data projected in 2026 and topline data in 2027.
  • ALG-055009 (MASH): Phase 2a topline data demonstrated statistically significant reductions in liver fat. The company is evaluating options to fund continued development, including potential out-licensing.
  • ALG-097558 (Coronavirus): Phase 1 studies are complete. Future development is expected to be funded by external sources, including approximately $15.3 million in federal funds from NIAID/NIH.
• Key Risks:
  • Profitability: The company has never generated revenue from product sales and may never achieve profitability. Future losses are expected.
  • Financing: Failure to obtain necessary capital could force the company to delay, limit, or terminate product development.
  • Regulatory & Clinical: High uncertainty regarding the success of clinical trials and regulatory approvals. The company has no experience in filing New Drug Applications (NDAs).
  • Warrant Liability: The 2023 common warrants are classified as a liability and remeasured at fair value each period, causing significant volatility in reported net income/loss.

Investor Verification Checklist

• Warrant Liability Impact: Verify the extent to which the reported net income is driven by the non-cash change in fair value of the 2023 common warrants ($63.2 million gain) versus operational performance.
• Cash Burn Rate: Confirm the actual cash burn rate from operating activities ($36.4 million used in six months) against the $122.9 million cash balance to validate the 12-month runway estimate.
• Revenue Recognition: Review the terms of the Amoytop collaboration agreement to understand the timing of future revenue recognition from the recent extension payments.
• Capital Structure: Note the dual-class stock structure (voting vs. non-voting) and the significant number of pre-funded warrants (4.2 million shares) that are immediately exercisable, which could impact dilution.
• External Funding Reliance: Assess the dependency on external funding (e.g., NIAID grants) for the coronavirus program and the potential risks if such funding is delayed or reduced.